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Anticancer activityAbstract A new series of pyrazoline analogs was furnished and evaluated for their in vitro antican-
cer efﬁcacies against human non-small-cell lung cancer cell line A549. Claisen–Schmidt condensa-
tion between intended acetophenone compound and different substituted aldehydes resulted in the
formation of corresponding chalcones which were cyclized using hydrazine hydrate to yield the ﬁnal
pyrazoline intermediates. a-Naphthyl isothiocyanate was prepared from benzoyl chloride and
a-naphthyl amine through a-naphthyl thiourea to react with pyrazoline intermediates to furnish
title compounds 10a–h, disubstituted pyrazolines in good yields and purity. All ﬁnal analogs were
screened for their anticancer potential using MTT and SRB assay in addition to the determination
of their cytotoxic nature. Final compounds revealed a good deal of potential against A549 cell lines
with reasonable level of cytotoxic nature, particularly analogs with ﬂuorine and thiomethyl and
methoxy functional group demonstrated good potencies. SAR showed that the activity level varied
with the variation in the nature of substituent present on the phenyl ring attached to the C-4
position of the pyrazoline ring. This study revealed the efﬁcacies of presented molecules for further
development as anticancer congeners. The structures of ﬁnal compounds were conﬁrmed with the
aid of FT-IR, 1H NMR, 13C NMR spectroscopy and CHN analysis.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
In 2012, cancers account to around 8.2 million deaths world-
wide making it the leading cause of death (Globocan, 2012).
Some types of cancers like breast, lung, liver, colorectal and
stomach cancers are among the most common cause of deaths
due to cancer each year. The use of tobacco led to increased
mortality over 20% with biggest risk factor globally with
around 70% lung cancer death ﬁgures. Within the next few
decades, it is expected that ﬁgure of yearly deaths due to cancer
will raise from 14 million in 2014 to 22 million (WHO). Thus,Arabian
2 Z.-H. Lu et al.there has been a continued struggle to search novel anticancer
agents with new mode of action, as these chemotherapeutic
drugs are still the important ones in cancer treatment at hospi-
tal settings apart from irradiation and surgical options (Chen
et al., 2006). Unfortunately, the level of toxicity exercised by
most of the newly emerging agents and the emergence of cellu-
lar drug resistance remained the most considerable difﬁculty in
anticancer drug discovery progress (Cozzi, 2003).
Diazoles like pyrazole and pyrazoline moiety have attracted
much attention due to their wide range of biological activities,
particularly anticancer action (Shaharyar et al., 2010; Congiu
et al., 2010; Havrylyuk et al., 2009). The 1H-indole-2,3-dione
is the privileged scaffold in modern medicinal chemistry which
have a broad spectrum of the biological activity and the wide
possibility to the chemical modiﬁcation. On the other hand,
intermediate derivatives with trimethoxy functional group con-
stitute an important class of compounds for new drug develop-
ment against lung cancer A549 cell lines (Kim et al., 2002). In
addition, incorporation of a-naphthyl isothiocyanate to build
a novel class of drug analogs has been successfully emerged
recently yielding azoles (Patel and Park, 2014). Pyrazoline moi-
ety represents an important class of compounds considered
worthy in drug designing (Rahman and Siddiqui, 2010) and
ﬁnally, the present study revealed pyrazole pharmacophore as
a central active ring which has already known to have potent
anticancer efﬁcacies (Pal et al., 2012). 3,5-Disubstituted pyraz-
oline analogs were recently decorated with substituted aromatic
functional groups and inspected for their reasonable anticancer
potential against lung cancer cell line A549 (Yar et al., 2007) in
addition to the similar anticancer potential of new steroidal
pyrazolines (Shamsuzzaman et al., 2012). It was recently
proved that substitution at different positions of pyrazoline
ring led to increased potency of the resultant compound as
anticancer agents (Bashir et al., 2011; Havrylyuk et al., 2011).
Hence, in the present investigation, we have furnished 3,5-
disubstituted pyrazoline analogs and examined their in vitro
anticancer potential which was found in a noticeable range.
2. Materials and methods
All chemicals were purchased from Sigma–Aldrich Chemical
Co. The solvent was removed at aspirator pressure using a
rotary evaporator. TLC was performed with Merck precoated
TLC plates, and the compounds were made visible using a
ﬂuorescent inspection lamp and iodine vapor. Gravity chroma-
tography was done with Merck silica gel 60 (70–230 mesh).
The melting points were recorded in open capillary tubes
and are uncorrected. FT-IR spectra were recorded on FT-IR
Shimadzu (potassium bromide pellets) spectrometer (4000–
400 cm1). 1H and 13C NMR spectra were determined as
DMSO solution at 400 and 100 MHz using TMS as an internal
standard. Elemental analyses were performed on a Perkin
Elmer EAL 240 elemental analyzer. All new compounds
yielded spectral data consistent with the proposed structure
and microanalysis within ±0.4% of the theoretical values.
2.1. General synthetic procedure for substituted phenyl-1-(3,4,5-
trimethoxyphenyl)prop-2-en-1-ones (2a–h)
To a continuously stirred solution of 0.5 mol of 3,4,5-trimeth-
oxy acetophenone (1) in ethanol, the solution of 5 mL NaOHPlease cite this article in press as: Lu, Z.-H. et al., Accessing anti-human lung tumor
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10 mL of petroleum ether was added with continuous stirring.
The resulting mixture was allowed to stand overnight and then
after 4 h stirring, the mixture was poured into crushed ice fol-
lowed by neutralization with HCl. The solid thus separated
was ﬁltered and dried over vacuum pump and puriﬁed from
ethanol to furnish (2a–h).
2.2. General synthetic procedure for substituted phenyl-3-(3,4,
5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazoles (3a–h)
To a solution of substituted phenyl-1-(3,4,5-trimethoxy-
phenyl)prop-2-en-1-ones (2a–h) in ethanol, 99% hydrazine
hydrate was added dropwise and the resulting mixture was
heated under reﬂux for 7–9 h. After the completion of the
reaction as checked by the TLC, the reaction mixture was
cooled and poured onto crushed ice. The solid thus obtained
was ﬁltered and dried using a vacuum pump to obtain ﬁnal
intermediates (3a–h) after recrystallization in ethanol. For
example, 3a: Yield 74%, m.p. 192–193 C, FT-IR (KBr):
3430, 3258 (NH), 3068 (aromatic CAH stretch), 2822 (OACH3
stretch), 1594 (C‚N), 1566 (aromatic C‚C stretch), 1245
(ArO); 1H NMR (DMSO-d6) d: 11.29 (1H, bs, NH, D2O
exchangeable), 7.42–7.26 (7H, m, ArAH), 6.59 (2H, s, H-2 &
H-6, trimethoxyphenyl ring), 6.33–6.46 (1H, m, CH, H-4,
pyrazoline), 3.79 (9H, s, 3-OCH3), 3.39–3.64 (m, 2H, CH2,
H-5, H-50-pyrazoline, cis and trans), Anal Calcd for
C22H22N2O3: C, 72.91; H, 6.12; N, 7.73; Found: C, 72.76; H,
6.29; N, 7.62.
2.3. Synthesis of a-naphthylthiourea (8)
To a freshly prepared 0.06 mol NH4SCN solution in acetone,
0.06 mol of benzoyl chloride was added drop wise and the
mixture was reﬂuxed for half an hour. Then, 0.06 mol of
a-naphthyl amine (6) in acetone was added in one part at
reﬂux temperature and the resulting reaction mixture was
again reﬂuxed for half an hour. After the completion of the
reaction, the mixture was poured with gentle stirring which
formed precipitates of compound 7 after ﬁltration. To a stirred
solution of 10% NaOH, intermediate 7 was added in one por-
tion at around 80 C and after half an hour, the mixture was
ﬁltered on a vacuum pump to eliminate insoluble material.
The resulting solution was treated with conc. HCl and pH
was adjusted at 8 with NH4OH to remove benzoic acid. The
precipitates thus formed were ﬁltered over a vacuum pump,
washed with water and dried to give a-naphthylthiourea (8)
after recrystallization with methanol in 86% of yield, m.p.
193–197 C.
2.4. Synthesis of a-naphthyl isothiocyanate (9)
In 100 mL of chlorobenzene, 0.05 mol of a-naphthylthiourea
(8) was reﬂuxed until complete evaluation of ammonia, gener-
ally up to 45 min. The reaction mixture was reﬂuxed for 9 h
and after the completion of the reaction, chlorobenzene was
removed under vacuum pressure to furnish residue of
a-naphthyl isothiocyanate (9) as pale yellow crystals, as
extracted using boiling hexane which was removed under vac-
uum pump pressure on a rotary evaporator. 9: colorless nee-
dles (recrystallization in hexane), yield: 85%, m.p. 58–59 C.cell line (A549) potential of newer 3,5-disubstituted pyrazoline analogs. Arabian
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5-substituted phenyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-
1H-pyrazole-1-carbothioamides (10a–h)
To a solution of 0.1 mol of substituted phenyl-3-(3,4,5-trime-
thoxyphenyl)-4,5-dihydro-1H-pyrazoles (3a–h) in ethanol
(20 mL), 0.1 mol of a-naphthyl isothiocyanate (9) and the reac-
tion mixture was reﬂuxed for 4–8 h. After the completion of
the reaction as checked by the TLC, the mixture was cooled
and then poured onto crushed ice. The solid thus obtained
was ﬁltered, washed with water and dried over vacuum pump
to yield ﬁnal desired compounds 10a–h.
2.5.1. N,5-di(naphthalen-1-yl)-3-(3,4,5-trimethoxyphenyl)-4,5-
dihydro-1H-pyrazole-1-carbothioamide (10a)
Yield 65%, m.p. 213–214 C, FT-IR (KBr): 3070 (aromatic
CAH stretch), 3222 (NH), 2813 (OACH3 stretch), 1587
(C‚N), 1572 (aromatic C‚C stretch), 1327 (CAN), 1229
(ArO), 1133 (C‚S); 1H NMR (DMSO-d6) d: 10.28 (1H, s,
NH), 7.59–7.17 (14H, m, ArAH), 6.55 (2H, s, H-2 & H-6, tri-
methoxyphenyl ring), 5.51–5.47 (1H, m, CH, H-4, pyrazoline),
3.74 (9H, s, 3-OCH3), 3.55 (1H, dd, J= 11.6 Hz and 17.1 Hz,
H-5, CH2, pyrazoline ring, trans), 3.15 (1H, dd, J= 5.6 Hz,
17.7 Hz, H-5, CH2, pyrazoline ring, cis).
13C NMR (DMSO-
d6) d: 175.2 (1C, C‚S), 155.6 (1C, C-1, pyrazoline), 153.3,
152.7, 150.6 (3C, CAOCH3), 144.3–121.9 (23C, ArAC), 67.1
(1C, C-4, pyrazoline), 65.5 (3C, OCH3), 46.5 (1C, C-5, pyraz-
oline). Anal Calcd for C33H29N3O3S: C, 72.37; H, 5.34; N,
7.67; Found: C, 72.11; H, 5.51; N, 7.54.
2.5.2. N-(naphthalen-1-yl)-5-p-tolyl-3-(3,4,5-
trimethoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
(10b)
Yield 51%, m.p. 226–228 C, FT-IR (KBr): 3075 (aromatic
CAH stretch), 3230 (NH), 2809 (OACH3 stretch), 1588
(C‚N), 1566 (aromatic C‚C stretch), 1333 (CAN), 1233
(ArO), 1134 (C‚S); 1H NMR (DMSO-d6) d: 10.33 (1H, s,
NH), 7.49–7.21 (11H, m, ArAH), 6.61 (2H, s, H-2 & H-6, tri-
methoxyphenyl ring), 5.55–5.50 (1H, m, CH, H-4, pyrazoline),
3.87 (9H, s, 3-OCH3), 3.59 (1H, dd, J= 11.3 Hz and 17.5 Hz,
H-5, CH2, pyrazoline ring, trans), 3.21 (1H, dd, J= 5.5 Hz,
17.3 Hz, H-5, CH2, pyrazoline ring, cis). 1.31 (3H, s, CH3).
13C NMR (DMSO-d6) d: 174.9 (1C, C‚S), 155.1 (1C, C-1,
pyrazoline), 154.5, 152.4, 148.7 (3C, CAOCH3), 145.2–119.2
(20C, ArAC), 67.7 (1C, C-4, pyrazoline), 65.9 (3C, OCH3),
46.9 (1C, C-5, pyrazoline). Anal Calcd for C30H29N3O3S: C,
70.43; H, 5.71; N, 8.21; Found: C, 70.61; H, 5.49; N, 8.02.
2.5.3. 5-(4-(Methylthio)phenyl)-N-(naphthalen-1-yl)-3-(3,4,5-
trimethoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
(10c)
Yield 60%, m.p. 264–266 C, FT-IR (KBr): 3067 (aromatic
CAH stretch), 3229 (NH), 2817 (OACH3 stretch), 1587
(C‚N), 1559 (aromatic C‚C stretch), 1336 (CAN), 1221
(ArO), 1125 (C‚S); 1H NMR (DMSO-d6) d: 10.22 (1H, s,
NH), 7.53–7.19 (11H, m, ArAH), 6.49 (2H, s, H-2 & H-6, tri-
methoxyphenyl ring), 5.53–5.45 (1H, m, CH, H-4, pyrazoline),
3.83 (9H, s, 3-OCH3), 3.53 (1H, dd, J= 11.5 Hz and 17.2 Hz,
H-5, CH2, pyrazoline ring, trans), 3.12 (1H, dd, J= 5.8 Hz,
17.1 Hz, H-5, CH2, pyrazoline ring, cis). 2.33 (3H, s, SCH3).Please cite this article in press as: Lu, Z.-H. et al., Accessing anti-human lung tumor
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pyrazoline), 153.2, 152.8, 149.0 (3C, CAOCH3), 146.1–123.7
(20C, ArAC), 68.3 (1C, C-4, pyrazoline), 66.1 (3C, OCH3),
46.7 (1C, C-5, pyrazoline). Anal Calcd for C30H29N3O3S2: C,
66.27; H, 5.38; N, 7.73; Found: C, 66.42; H, 5.19; N, 7.90.
2.5.4. 5-(4-Fluorophenyl)-N-(naphthalen-1-yl)-3-(3,4,5-
trimethoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
(10d)
Yield 71%, m.p. 231–232 C, FT-IR (KBr): 3081 (aromatic
CAH stretch), 3222 (NH), 2810 (OACH3 stretch), 1591
(C‚N), 1571 (aromatic C‚C stretch), 1320 (CAN), 1217
(ArO), 1131 (C‚S); 1H NMR (DMSO-d6) d: 10.25 (1H, s,
NH), 7.51–7.22 (11H, m, ArAH), 6.58 (2H, s, H-2 & H-6, tri-
methoxyphenyl ring), 5.51–5.49 (1H, m, CH, H-4, pyrazoline),
3.81 (9H, s, 3-OCH3), 3.56 (1H, dd, J= 11.6 Hz and 17.1 Hz,
H-5, CH2, pyrazoline ring, trans), 3.17 (1H, dd, J= 5.7 Hz,
17.4 Hz, H-5, CH2, pyrazoline ring, cis).
13C NMR (DMSO-
d6) d: 173.8 (1C, C‚S), 156.3 (1C, C-1, pyrazoline), 154.7,
151.9, 149.9 (3C, C‚OCH3), 144.1–116.8 (19C, ArAC), 67.4
(1C, C-4, pyrazoline), 65.1 (3C, OCH3), 47.4 (1C, C-5, pyraz-
oline). Anal Calcd for C29H26FN3O3S: C, 67.55; H, 5.08; N,
8.15; Found: C, 67.69; H, 4.96; N, 8.38.
2.5.5. 5-(4-Bromophenyl)-N-(naphthalen-1-yl)-3-(3,4,5-
trimethoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
(10e)
Yield 57%, m.p. 202–204 C, FT-IR (KBr): 3077 (aromatic
CAH stretch), 3220 (NH), 2821 (OACH3 stretch), 1583
(C‚N), 1562 (aromatic C‚C stretch), 1327 (CAN), 1241
(ArO), 1142 (C‚S); 1H NMR (DMSO-d6) d: 10.19 (1H, s,
NH), 7.61–7.26 (11H, m, ArAH), 6.51 (2H, s, H-2 & H-6, tri-
methoxyphenyl ring), 5.54–5.52 (1H, m, CH, H-4, pyrazoline),
3.77 (9H, s, 3-OCH3), 3.53 (1H, dd, J= 11.7 Hz and 17.3 Hz,
H-5, CH2, pyrazoline ring, trans), 3.11 (1H, dd, J= 5.6 Hz,
17.7 Hz, H-5, CH2, pyrazoline ring, cis).
13C NMR (DMSO-
d6) d: 174.6 (1C, C‚S), 154.8 (1C, C-1, pyrazoline), 154.1,
152.2, 150.1 (3C, CAOCH3), 147.2–123.2 (19C, ArAC), 66.9
(1C, C-4, pyrazoline), 65.5 (3C, OCH3), 46.8 (1C, C-5, pyraz-
oline). Anal Calcd for C29H26BrN3O3S: C, 60.42; H, 4.55; N,
7.29; Found: C, 60.30; H, 4.71; N, 7.50.
2.5.6. N-(naphthalen-1-yl)-5-(pyridin-4-yl)-3-(3,4,5-
trimethoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
(10f)
Yield 49%, m.p. 199–201 C, FT-IR (KBr): 3072 (aromatic
CAH stretch), 3218 (NH), 2813 (OACH3 stretch), 1577
(C‚N), 1579 (aromatic C‚C stretch), 1322 (CAN), 1230
(ArO), 1129 (C‚S); 1H NMR (DMSO-d6) d: 10.41 (1H, s,
NH), 8.11 (dd, J= 7.2, 1.8 Hz, 1H, pyridine), 7.55–7.20
(10H, m, ArAH), 6.55 (2H, s, H-2 & H-6, trimethoxyphenyl
ring), 5.57–5.52 (1H, m, CH, H-4, pyrazoline), 3.78 (9H, s,
3-OCH3), 3.51 (1H, dd, J= 11.6 Hz and 17.0 Hz, H-5, CH2,
pyrazoline ring, trans), 3.18 (1H, dd, J= 5.5 Hz, 17.6 Hz, H-
5, CH2, pyrazoline ring, cis).
13C NMR (DMSO-d6) d: 175.0
(1C, C‚S), 155.5 (1C, C-1, pyrazoline), 153.4, 152.7, 150.5
(3C, CAOCH3), 145.2–120.4 (18C, ArAC), 67.6 (1C, C-4, pyr-
azoline), 66.3 (3C, OCH3), 45.8 (1C, C-5, pyrazoline). Anal
Calcd for C28H26N4O3S: C, 67.45; H, 5.26; N, 11.24; Found:
C, 67.28; H, 5.47; N, 11.13.cell line (A549) potential of newer 3,5-disubstituted pyrazoline analogs. Arabian
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trimethoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
(10g)
Yield 67%, m.p. 214–216 C, FT-IR (KBr): 3070 (aromatic
CAH stretch), 3233 (NH), 2819 (OACH3 stretch), 1581
(C‚N), 1575 (aromatic C‚C stretch), 1334 (CAN), 1235
(ArO), 1122 (C‚S); 1H NMR (DMSO-d6) d: 10.36 (1H, s,
NH), 7.48–7.17 (11H, m, ArAH), 6.60 (2H, s, H-2 & H-6, tri-
methoxyphenyl ring), 5.51–5.44 (1H, m, CH, H-4, pyrazoline),
3.80 (9H, s, 3-OCH3), 3.60 (1H, dd, J= 11.6 Hz and 17.1 Hz,
H-5, CH2, pyrazoline ring, trans), 3.16 (1H, dd, J= 5.4 Hz,
17.8 Hz, H-5, CH2, pyrazoline ring, cis).
13C NMR (DMSO-
d6) d: 175.5 (1C, C‚S), 156.3 (1C, C-1, pyrazoline), 154.5,
151.6, 149.1 (3C, CAOCH3), 147.1–126.6 (19C, ArAC), 68.3
(1C, C-4, pyrazoline), 65.8 (3C, OCH3), 46.9 (1C, C-5, pyraz-
oline). Anal Calcd for C29H26ClN3O3S: C, 65.47; H, 4.93; N,
7.90; Found: C, 65.33; H, 5.08; N, 8.05.
2.5.8. 5-(4-Methoxyphenyl)-N-(naphthalen-1-yl)-3-(3,4,5-
trimethoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
(10h)
Yield 62%, m.p. 205–206 C, FT-IR (KBr): 3075 (aromatic
CAH stretch), 3228 (NH), 2811 (OACH3 stretch), 1580
(C‚N), 1572 (aromatic C‚C stretch), 1319 (CAN), 1222
(ArO), 1139 (C‚S); 1H NMR (DMSO-d6) d: 10.31 (1H, s,
NH), 7.52–7.24 (11H, m, ArAH), 6.52 (2H, s, H-2 & H-6, tri-
methoxyphenyl ring), 5.53–5.50 (1H, m, CH, H-4, pyrazoline),
3.85 (9H, s, 3-OCH3), 3.76 (3H, s, OCH3), 3.58 (1H, dd,
J= 11.6 Hz and 17.1 Hz, H-5, CH2, pyrazoline ring, trans),
3.20 (1H, dd, J= 5.3 Hz, 17.2 Hz, H-5, CH2, pyrazoline ring,
cis). 13C NMR (DMSO-d6) d: 174.8 (1C, C‚S), 154.9 (1C, C-
1, pyrazoline), 153.1, 152.4, 148.8 (3C, CAOCH3), 145.3–121.6
(20C, ArAC), 67.9 (1C, C-4, pyrazoline), 65.7 (3C, OCH3),
47.6 (1C, C-5, pyrazoline). Anal Calcd for C30H29N3O4S: C,
68.29; H, 5.54; N, 7.96; Found: C, 68.39; H, 5.41; N, 7.82.
3. In vitro evaluation of anticancer activity
3.1. SRB (Sulforhodamine B) assay
Using RPMI 1640 medium with 10% fetal bovine serum and
2 mM L-glutamine, the cell lines were grown. 96 well microtiter
plates were used to inoculate cells depending on the doubling
time of individual cell lines in 90 lL at plating densities. The
microtitre plates were incubated at 37 ± 1 C, 5% CO2, 95%
air and 100% relative humidity for 24 h after inoculation and
before the addition of compounds to be screened. After incuba-
tion, cell population was measured for each line at the time on
which title drug was added (Tz) ﬁxing one plate of each cell line
with TCA. Respective concentrations of the title compounds
were prepared using DMSO at 400-fold. An aliquot of
100 mL of each test compound concentration was added to
the appropriate well that already has 100 mL of medium con-
taining the cells followed by incubation of these plates for
48 h at 37 C (Skehn et al., 1990). Cells were ﬁxed in situ by
the gentle addition of 50 mL of cold 10% w/v TCA and
incubated for 60 min at 4 C. The supernatant was discarded
and the plates were thoroughly washed and air dried. Then,
50 lL of 0.4% w/v SBR solution in 1% CH3COOH was added
to each well and incubated for 20 min at RT. After staining,
unbound dye was recovered and the residual dye wasPlease cite this article in press as: Lu, Z.-H. et al., Accessing anti-human lung tumor
Journal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.11.002eliminated by washing thoroughly with 1% CH3COOH and
well plates were air dried. 10 mM Trizma base was used to
dissolve the bound stain and the absorbance was read on an
ELISA plate reader (690 nm reference wavelength) at a wave-
length of 515 nm. With reference to the control well, % growth
was determined for each drug plate and is expressed as the ratio
of average absorbance of the test well to the average
absorbance of the control wells · 100. Using the six absor-
bance measurements [time zero (Tz), control growth (C), and
test growth in the presence of drug at the four concentration
levels (Ti)], the percentage growth was calculated at each of
the drug concentration levels. Percentage growth inhibition
was calculated as: [(Ti  Tz)/(C  Tz)] · 100 for concentra-
tions for which TiP Tz and [(Ti  Tz)/Tz] · 100 for concen-
trations for which Ti < Tz. For the each test compound, the
dose parameters were calculated in which GI50 level was calcu-
lated using the equation [(Ti  Tz)/(C  Tz)] · 100 = 50 which
represents the drug concentration resulting in a 50% reduction
in the net protein increase (as measured by SRB staining) in
control cells during the drug incubation. The TGI level which
expressed the tested drug concentration resulting in total
growth inhibition was determined from Ti = Tz. LC50 values
expressed concentration of drug resulting in a 50% reduction
in the measured protein at the end of the drug treatment as
compared to that at the beginning and indicating a net loss of
cells was calculated from [(Ti  Tz)/Tz] · 100 = 50.
3.2. Cytotoxicity evaluation
3.2.1. MTT assay
MTT assay was performed according to the procedure given in
the literature (Bopp and Lettieri, 2008) using control adriamy-
cin. A 96-Well plate was used to seed the cells followed by
incubation for 24 h at 37 C. The respective concentrations
of tested compounds (100 mg) were added in the wells of the
plate. Controls were maintained to determine the control cell
survival (CS) and the percentage of live cells after culture.
After incubation, the medium was removed and 20 lL of
MTT reagent was added in each plate followed by incubation
for 4 h at 37 C. The wells for formazan crystal formation were
observed under microscope. The yellowish MTT is reduced to
dark colored formazan by viable cells only. After the removal
of medium, 200 lL of DMSO was added and incubated at
37 C for 10 min. The color developed was quantiﬁed with
an ELISA plate reader (570 nm). The CS is expressed as per-
centage (T/C · 100), where T = test, C = average of control
readings. %Cytotoxicity was calculated by: %Cytotoxicity =
100 %Viability.4. Results and discussion
4.1. Chemistry
Scheme 1 outlines chemical reaction sequences and conditions
required to furnish ﬁnal compounds 10a–h. Solvents and
reagents were used as received or were dried prior to use as
needed. Claisen–Schmidt condensation yielded corresponding
chalcones (2a–h) from 3,4,5-trimethoxy acetophenone (1) and
appropriate aldehyde derivatives in the presence of base
KOH (Beyhan et al., 2013). Hydrazine hydrate was reacted
with chalcones leading to the formation of ﬁnal intermediatecell line (A549) potential of newer 3,5-disubstituted pyrazoline analogs. Arabian
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Scheme 1 Synthetic protocol for desired pyrazoline analogs (10a–h). Reagents and conditions: (i) KOH, ethanol, stirring; (ii)
NHNH2ÆH2O, EtOH, reﬂux; (iii) NH4SCN, acetone, reﬂux; (iv) acetone, reﬂux; (v) 10% NaOH, 80 C, stirring; (vi) chlorobenzene, reﬂux;
(vii) ethanol, reﬂux.
Anti-human lung tumor cell line (A549) potential of 3,5-disubstituted pyrazoline analogs 5pyrazolines, 3a–h (Insuasty et al., 2013). In 1H NMR spectra
of compound 3a, ring NH appeared as a broad singlet at
11.29 ppm, exchangeable with D2O. In addition, CH proton
of the pyrazoline ring resonated at 6.33–6.46 ppm as multiplet
signals whereas CH2 protons appeared for the cis and trans
prochiral signals as multiplets in range 3.39–3.64 ppm and data
were in accordance with literature (Hassan, 2013). Simulta-
neously, synthesis of a-naphthyl isothiocyanate was carried
out from benzoyl chloride (4) and NH4SCN to give benzoyl
isothiocyanate (5) which was treated with a-naphthyl amine
(6) to furnish corresponding benzamide moiety (7). This benz-
amide was heated in 10% NaOH and then acidiﬁed (up to
basic pH) to synthesize a-naphthylthiourea (8) (Rasmussen
et al., 1998; Frank and Smith, 1955). Reﬂuxing of 8 in chloro-
benzene gave a-naphthyl isothiocyanate (9) in 85% of yield
(Cymerman-Craig et al., 1963) using literature method.
Freshly prepared isothiocyanate derivative 9 was reﬂuxed in
ethanol with intermediate pyrazolines 3a–h to yield the desired
ﬁnal compounds 10a–h in 49–71% of yields (Ali et al., 2007).
The FT-IR spectra of the compounds 10a–h afforded
pyrazoline C‚N and CAN stretchings (1591–1577 cm1 and
1336–1319 cm1), thiocarbamoyl group NAH stretching
(3233–3218 cm1) and CAS stretching (1142–1122 cm1)
bands. 1H NMR spectra of compounds 10a–h gave singlet
for ANH proton in the range 10.41–10.19 ppm, whereas
pyrazoline CH2 and CH proton resonated as doublet and
multiplet in the range 3.63–3.49 ppm and 5.57–5.47 ppm,
respectively. In the pyrazoline moiety, CH2 protons with chi-
rality revealed the respective peaks as two distinct doublets
of doublet centered at d 3.11–3.63 ppm (Jois et al., 2014;
Ovais et al., 2014) indicating the diaxial conﬁguration of those
vicinal protons. Protons of trimethoxy functional group gave a
peak in the range 3.87–3.74 ppm in the 1H NMR spectra of
10a–h. 13C NMR spectra of compounds 10a–h gave a peakPlease cite this article in press as: Lu, Z.-H. et al., Accessing anti-human lung tumor
Journal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.11.002in the range 175.5–173.8 ppm for C‚S carbon atoms, whereas
pyrazoline carbon atoms C-1, C-4 and C-5 appeared at around
175 ppm, 67 ppm and 45 ppm, respectively. Trimethoxy func-
tional group gave its characteristic carbon atom peaks in the
range 154.7–148.7 ppm. All of the novel compounds gave C,
H and N analyses within 0.04% points from the theoretical
values. The structures of the new compounds were fully sup-
ported through their spectroscopic data (FT-IR, 1H NMR,
13C NMR spectroscopy and CHN analysis).4.2. Biology
In vitro evaluation of anticancer productiveness was carried
out for analogs 10a–h and results are summarized in Table 1.
From the bioassay results, it is clear that the sorts of analogs
designed and built via efﬁcient chemical transformations had
interesting biological action toward tumor cell line studied.
Compounds with substitution of ﬂuorine and alkoxy function-
alities showed increased potencies than unsubstituted analogs.
Among EWD and ED substituents, activity order followed as
Cl > Br > F and CH3 > OCH3 > SCH3. All compounds
were examined for their cytotoxicity against human non-
small-cell lung cancer cell line A549 using MTT assay with ref-
erence to control drug adriamycin and results are expressed in
terms of %cytotoxicity.
From the bioassay determination, it can be said that 10d
with highly electronegative ﬂuorine substituent was the most
potent with 71.24% cytotoxic potential as compared to control
adriamycin at 80.55%. Additionally, compounds with thio-
methyl functionality (10c) and alkoxy functional group (10h)
had the considerable cytotoxic abilities against A549 cell lines.
The activity then decreased for compounds with other halogen
functional groups like bromine (10e, cytotoxicity: 60.89%) andcell line (A549) potential of newer 3,5-disubstituted pyrazoline analogs. Arabian
Table 1 Anti-human lung tumor cell Line (A549) activity of ﬁnal compounds 10a–h.
Entry R MTT assay SRB assaya
%Cytotoxicity LC50 (lM) TGI (lM) GI50 (lM) GI50 (lg/mL)
10a 36.21 >100 >100 50.34 27.57
10b
H3C
22.91 >100 >100 84.33 43.15
10c
S
67.58 >100 61.24 28.27 15.37
10d
F
71.24 >100 46.76 22.13 11.41
10e
Br
60.89 >100 >100 52.67 30.36
10f N 44.82 >100 >100 55.04 27.44
10g
Cl
53.23 >100 >100 73.22 38.96
10h
H3CO
66.50 >100 78.99 31.56 16.65
ADR – 80.55 >100 >100 0.411 0.411
LC50 = concentration of drug causing 50% cell kill.
TGI = concentration of drug causing total inhibition of cell growth.
GI50 = concentration of drug causing 50% inhibition of cell growth.
ADR= adriamycin, positive control compound.
a Each value is the mean of three independent experiments.
6 Z.-H. Lu et al.chlorine (10g, cytotoxicity: 53.23%). Furthermore, all com-
pounds were checked for their cytotoxicity (GI50) using SRB
assay, in which a similar trend was followed in case of antican-
cer efﬁcacies as in MTT assay. Compounds 10d, 10c and 10h
with ﬂuorine, methylthio and methoxy groups exhibited
11.41 lg/mL, 15.37 lg/mL and 16.65 lg/mL of GI50 levels
against A549 cell line, respectively. These three compounds
are considered to have some anticancer potential among all
studied. Furthermore, compounds 10d, 10c and 10h appeared
with most potent TGI level at 46.76 lM, 61.24 lM and
78.99 lM, respectively when compared to the control drug
adriamycin at >100 lM of TGI. In general, all compounds
revealed a noticeable action against A549 cell lines in both
MTT and SRB bioassay as compared to the potencies of con-
trol drug adriamycin.5. Conclusion
To sum up, a series of trimethoxy functionality based pyrazo-
lines has been furnished with variety of aryl substituents at the
C-4 position of pyrazoline moiety via Claisen–Schmidt
condensation. Newer analogs were characterized adequately
and analysis results are in accurate accordance with proposed
structures. Compounds expressed anticancer potential against
non-small-cell lung cancer cell line A549 with %cytotoxicity in
the range 36.21–71.24 in MTT assay where as potent GI50 level
in SRB assay in the range 11.41–43.15 lg/mL as well as three
compounds furnished TGI level in the range 46.76–78.99 lM.
Compounds with ﬂuorine atom exhibited signiﬁcant antican-
cer potency followed by those involving substitution of
thiomethyl and methoxy functionalities. All these pharmaco-
logical results suggest further research in this area to enhance
the potencies of the type of molecules presented herewith.Please cite this article in press as: Lu, Z.-H. et al., Accessing anti-human lung tumor
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